* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
Dauch Corporation (DCH.L) listed on the Main Market, after a delisting of Dowlais Group plc, which it acquired as part of its own listing. Dauch Corporation is a premier global Tier 1 automotive supplier headquartered in Detroit, Michigan, specialising in the design, engineering, and manufacturing of driveline and metal forming technologies for electric, hybrid, and internal combustion vehicles.
Delistings:
Dowlais Group plc delisted from the Main Market after being acquired by Dauch Corporation via a scheme of arrangement.
What’s baking in the oven?
Market Movers:***
14 January: GlobalData (DATA.L), the data, insight, and technology Companyexpects to submit its application to move to the Main Market from AIM and to take place on 5 March.
Banquet Buffet****
Ariana Resources 1.95p £54.41m (AAU.L)
The mineral exploration, development and production Company with gold project interests in Africa and Europe, reports the settlement of all outstanding loan balances with RiverFort Global Opportunities. Following the settlement of outstanding loan balance of $782,575.08 through the issuing of 40,435,311 ordinary shares in accordance with the loan terms and pricing under the Facility Agreement, Ariana will, however, retain access to the remaining undrawn $3m of the original $5m under the Facility Agreement, should it require additional loan financing during the next 3 years as it continues to advance the Dokwe Gold Project in Zimbabwe.
Aterian 28.50p £4.73m (ATN.L)
The Africa-focused critical metals exploration and development Company updates on its early-stage activities. This included reconnaissance and sampling programme which was recently completed at its Sua Pan Brine Project in Botswana. The programme has confirmed the presence of highly saline, alkaline, sodium-rich brines across the licence area, specifically identifying a sodium-carbonate-dominant brine system consistent with natural soda ash-style deposits. These results introduce a potentially attractive industrial minerals development pathway, alongside continued evaluation of the basin for various critical minerals. Although the results are reconnaissance they are highly encouraging and open a potentially attractive opportunity for industrial minerals development.
Cizzle Biotechnology Holdings 1.60p £5.55m (CIZ.L)
The UK-based developer of diagnostic tests for early-stage cancer report progress on patent applications. The protection has been granted by the Canadian intellectual property office for methods that measure the CIZ1B lung cancer biomarker. The Company has a strong patent portfolio and continues to seek additional protection in other key markets globally. In addition to its existing patent coverage in the US, a further application is likely to be granted in due course. This enhances the Company's ability to deliver its global commercial strategy following the first licence agreement with BIO for North America and the Caribbean.
Cobra Resources 4.45p £41.55m (COBR.L)
The mineral exploration and development Company advancing a potentially world-class ionic Rare Earth Element (REE) discovery at its Boland Project reports metallurgical tests. These are from historical pulps from the Head Prospect and are indicative of significant scalability beyond Boland for low-cost in-situ recovery of ionic heavy REEs. Diagnostic tests on composite pulp samples yielded excellent recoveries from the target horizon. These Recoveries are comparable to early-stage metallurgy results at Boland, where the Company has advanced metallurgical recoveries up to 68% Terbium and 63% Dysprosium through low-cost, low-impact techniques. These results represent an important step in the strategy to define a scalable resource across the Company’s significant palaeochannel landholding. Through strategic tenement acquisitions, Cobra now holds over 3,200km of prospective geology.
Eco Buildings Group 15.75p £18.82m (ECOB.L)
The innovator in prefabricated, green housing products, leveraging proven technology based on large glass fibre reinforced gypsum (GFRG) panels has agreed to deliver a Modular Hospital System for a Community Healthcare Project in Senegal. Under the arrangement, Eco Buildings will donate the complete modular hospital building system, utilising its proprietary low-carbon and durable construction technology. Amigos de Buba will fully fund and manage the transport, installation, and local delivery of the hospital, while G2 Invest, Eco Buildings' local JV partner in Senegal, will support site readiness, coordination, and local implementation alongside the municipal authorities. This donation is to demonstrate the adaptability of the Company’s technology for healthcare applications while ensuring that delivery, installation, and local coordination are managed by established third parties.
Futura Medical 1.20p £7.70m (FUM.L)
The consumer healthcare Group behind Eroxon that specialises in the development and global commercialisation of innovative and clinically proven sexual health products updates on trading for FY December 2025. Revenue of £1.7m is ahead of previously guided management expectations. The net cash was £3.4m following November’s Fund raise of £2.75m, and the Company expects to trigger a milestone payment from Haleon of $2.5m during H1 2026, as well as a tax credit refund of around $0.3m. This is expected to provide the Company with a cash runway to December 2026, which is in line with prior statements. The Board is undertaking a strategic review of the business and its operations which is expected to conclude in Q1 2026 and reported in the Company's finals expected to be released mid-April 2026.
Gem Diamonds 4.70p £3.99m (GEMD.L)
The global producer of high value diamonds which owns 70% of the Letšeng mine in Lesotho updates on Q4 2025 Trading from 1 October to 31 December. There were 20,961 carats recovered resulting in 90,354 carats for the year which is less then the 105,012 for FY 2024. Post Period end, a 193 carat white type II diamond was recovered. The highest price achieved in Q4 was $66 602 per carat for an 8.83 carat pink diamond. Six diamonds sold for more than $1.0m contributing $9.2m. All operational metrics were within or ahead of the revised guidance announced on 23 July 2025.
Goldstone Resources Limited 1.28p £12.10m (GRL.L)
The mining and development Company with projects in Ghana that range from grassroots exploration to production makes an Operational Update. The focus is on developing the Akrokeri-Homase project in south-western Ghana, which hosts a JORC Code compliant 602,000oz gold resource at an average grade of 1.77 g/t. The existing resource is confined to a 4km zone of the Homase Trend. The gold production has continued into 2026, with a gold pour of approximately 12 kilograms of doré completed at the end of January 2026. Mining has commenced on the near-surface oxide material from Pit 3 of the Homase Mine. Construction activities at Pad 6 are progressing and the geofabric and geomembrane installation is expected to commence later this month. In parallel, the Company is also preparing drill pad areas to support mine planning activities associated with Pit 5 and Pit 6, as part of its ongoing optimisation and forward planning for the mine.
Power Metal Resources 15.00p £17.05m (POW.L)
The mineral exploration Company and project incubator with a global project portfolio provided an update on the exploration programme at the Balthaga project in the Kingdom of Saudi Arabia. The Company is commencing the exploration expenditure required to increase its shareholding to 30%. As part of this, the Company is mobilising a team to carry out the next stage of exploration focused on defining drill targets. This drill target definition programme will be split into two phases. The initial phase focusing on a mapping and rock sampling programme targeting both previously defined targets and new targets. Phase two will focus on an infill soil geochemistry sampling programme over the anomalous Hugban intrusion corridor. This should enhance the Company’s strategic position in the project.
Tertiary Minerals 0.12p £4.64m (TYM.L)
The mineral exploration and development Company whose strategic focus is on energy transition metals reports Laboratory Results. The four holes completed during the Phase 3 drilling programme at Target A1 at its Mushima North Project in Zambia. The laboratory analytical results indicate further high-grade silver and copper mineralisation in the north of Target A1, which has a mineralisation footprint of 450m by up to 400m wide area, and remains open to the northwest, south/southeast and at depth. The prospect located 28km to the east of the historic Kalengwa copper-silver mine which is currently under redevelopment and is one of several targets to be evaluated at the Project. The exploration Target is planned to be released in the coming weeks and will form the basis of future planned programmes to commence at the start of the dry season this year and will support the production of a Maiden Mineral Resource Estimate by the end of 2026.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
